H. Michael Shepard

3.7k total citations · 2 hit papers
40 papers, 2.9k citations indexed

About

H. Michael Shepard is a scholar working on Cell Biology, Molecular Biology and Oncology. According to data from OpenAlex, H. Michael Shepard has authored 40 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Cell Biology, 24 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in H. Michael Shepard's work include Proteoglycans and glycosaminoglycans research (26 papers), Fibroblast Growth Factor Research (16 papers) and Glycosylation and Glycoproteins Research (11 papers). H. Michael Shepard is often cited by papers focused on Proteoglycans and glycosaminoglycans research (26 papers), Fibroblast Growth Factor Research (16 papers) and Glycosylation and Glycoproteins Research (11 papers). H. Michael Shepard collaborates with scholars based in United States, United Kingdom and Belarus. H. Michael Shepard's co-authors include G. J. Frost, Ping Jiang, Curtis B. Thompson, Anne Kultti, Daniel C. Maneval, Ping Jiang, Daniel D. Von Hoff, Haiyong Han, Clifford J. Whatcott and Michael A. Jacobetz and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

H. Michael Shepard

39 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

2012 837 citations Michael A. Jacobetz, Derek Chan et al. Gut profile →
Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer

2015 469 citations Clifford J. Whatcott, Caroline H. Diep et al. Clinical Cancer Research profile →

Peers

H. Michael Shepard

ONCOL

IMMUN

Michael W. Pickup United States

Esther N. Arwert United Kingdom

Meenakshi A. Chellaiah United States

Lars H. Engelholm Denmark

Paul E. Oberstein United States

Scott J. Dylla United States

Anne Kultti Finland

Ajeeta B. Dash United States

Theerawut Chanmee Thailand

Daniel Öhlund Sweden

Michael W. Pickup United States

H. Michael Shepard

1.9k ×1.1

ONCOL

1.8k ×1.6

812 ×1.2

929 ×1.7

IMMUN

783 ×1.5

Citations per year, relative to H. Michael Shepard H. Michael Shepard (= 1×) peers Michael W. Pickup

Countries citing papers authored by H. Michael Shepard

Since Specialization

Citations

This map shows the geographic impact of H. Michael Shepard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Michael Shepard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Michael Shepard more than expected).

Fields of papers citing papers by H. Michael Shepard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Michael Shepard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Michael Shepard. The network helps show where H. Michael Shepard may publish in the future.

Co-authorship network of co-authors of H. Michael Shepard

This figure shows the co-authorship network connecting the top 25 collaborators of H. Michael Shepard. A scholar is included among the top collaborators of H. Michael Shepard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Michael Shepard. H. Michael Shepard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Lin, Luz M. Londono, Özge Saatci, et al.. (2021). Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Research. 81(12). 3319–3332. 29 indexed citations

Li, Xiaoming, H. Michael Shepard, Chun‐Mei Zhao, et al.. (2018). Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clinical Cancer Research. 24(19). 4798–4807. 69 indexed citations

Marella, Mathieu, et al.. (2018). KIAA1199 expression and hyaluronan degradation colocalize in multiple sclerosis lesions. Glycobiology. 28(12). 958–967. 12 indexed citations

Infante, Jeffrey R., Ronald L. Korn, Lee S. Rosen, et al.. (2017). Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. British Journal of Cancer. 118(2). 153–161. 64 indexed citations

Hingorani, Sunil R., William Proctor Harris, J. Thaddeus Beck, et al.. (2016). Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research. 22(12). 2848–2854. 262 indexed citations

Whatcott, Clifford J., Caroline H. Diep, Ping Jiang, et al.. (2015). Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clinical Cancer Research. 21(15). 3561–3568. 469 indexed citations breakdown →

Shepard, H. Michael. (2015). Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy. Frontiers in Oncology. 5. 192–192. 59 indexed citations

Singha, Netai C., et al.. (2015). Abstract 982: Hyaluronan (HA) depletion increases tumor accessibility of T cell and therapeutic PD-L1 monoclonal antibody in HAhigh tumors. Cancer Research. 75(15_Supplement). 982–982. 1 indexed citations

Singha, Netai C., Chun‐Mei Zhao, Ping Jiang, et al.. (2014). Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy. Molecular Cancer Therapeutics. 14(2). 523–532. 110 indexed citations

10.

Paladini, Rudolph D., Ge Wei, Anirban Kundu, et al.. (2013). Mutations in the Catalytic Domain of Human Matrix Metalloproteinase-1 (MMP-1) That Allow for Regulated Activity through the Use of Ca2+. Journal of Biological Chemistry. 288(9). 6629–6639. 6 indexed citations

11.

Jiang, Ping, Daniel C. Maneval, Ramesh K. Ramanathan, et al.. (2013). Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors.. Cancer Research. 73(8_Supplement). 3375–3375. 2 indexed citations

12.

Jacobetz, Michael A., Derek Chan, Albrecht Neeße, et al.. (2012). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62(1). 112–120. 837 indexed citations breakdown →

13.

Maneval, Daniel C., Ramesh K. Ramanathan, Jeffrey R. Infante, et al.. (2012). Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors. Cancer Research. 72(8_Supplement). 2672–2672. 1 indexed citations

14.

Gompels, Luke, N. M. Malik, Leigh A. Madden, et al.. (2011). Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade. Arthritis Research & Therapy. 13(5). R161–R161. 10 indexed citations

15.

Thompson, Curtis B., H. Michael Shepard, P M O'Connor, et al.. (2010). Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models. Molecular Cancer Therapeutics. 9(11). 3052–3064. 235 indexed citations

16.

Pei, Jin, Juan Zhang, Percy F. Sumariwalla, et al.. (2008). Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Research & Therapy. 10(4). R73–R73. 33 indexed citations

17.

Sumariwalla, Percy F., Jin Pei, Juan Zhang, et al.. (2008). Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen‐induced arthritis. Arthritis & Rheumatism. 58(10). 3071–3080. 11 indexed citations

18.

Bookbinder, Louis H., Michael F. Haller, Monica L. Zepeda, et al.. (2006). A recombinant human enzyme for enhanced interstitial transport of therapeutics. Journal of Controlled Release. 114(2). 230–241. 212 indexed citations

19.

Linke, Steven P., Matthew P. Harris, Kristie Clarkin, et al.. (1997). p53-mediated accumulation of hypophosphorylated pRb after the G1 restriction point fails to halt cell cycle progression. Oncogene. 15(3). 337–345. 22 indexed citations

20.

Wen, Shu Fen, et al.. (1994). Retinoblastoma protein monoclonal antibodies with novel characteristics. Journal of Immunological Methods. 169(2). 231–240. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact